This online seminar will highlights recent advances in the use of next-generation sequencing to detect drug resistance mutations in patients with HIV or HCV.
Sanger sequencing and PCR have been the standard molecular methods in clinical diagnostics for decades, but NGS is now swiftly becoming a routine method in different areas of clinical diagnostics, including treatment management for viral diseases.
Vela Diagnostics has developed an automated qPCR and NGS workflow called Sentosa for targeted sequencing of human and viral DNA. Our speakers will discuss practical examples of the use of this workflow to aid clinical decision-making and patient management.
Gerd Michel, Chief Scientific Officer of VelaDx discusses examples of how the Sentosa workflow may be applied to HIV and HCV, delivering accurate genotyping information and in the detection of drug-resistant mutations.
Christophe Rodriguez of the University of Paris-Est-Creteil, discusses how his team used this automated workflow for HCV resistance testing. His presentation outlines how deep sequencing technology shows better performance than population sequencing in direct-acting antiviral-experienced patients awaiting retreatment.